French hospital tests new hope for Tough-to-Treat blood cancer
NCT ID NCT07392814
Summary
This early-stage study is testing whether adding the drug tocilizumab to a standard two-drug chemotherapy (venetoclax and azacitidine) is safe and tolerable for adults with acute myeloid leukemia (AML) who cannot receive the most intensive treatments. The main goal is to find the right dose by carefully monitoring 12 participants for side effects. Researchers will also track how patients respond to the treatment and how long benefits last.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA ACUTE MYELOID - AML are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU of Nantes
Nantes, 44000, France
Conditions
Explore the condition pages connected to this study.